(Q53851250)

21 May 2018

title

BHIVA treatment guidelines for tuberculosis (TB)/HIV infection 2005. (English)

1 reference

21 May 2018

1 reference

A L Pozniak

1

1 reference

21 May 2018

R F Miller

2

1 reference

21 May 2018

M C I Lipman

3

1 reference

21 May 2018

A R Freedman

4

1 reference

21 May 2018

L P Ormerod

5

1 reference

21 May 2018

M A Johnson

6

1 reference

21 May 2018

S Collins

7

1 reference

21 May 2018

S B Lucas

8

1 reference

21 May 2018

BHIVA Guidelines Writing Committee

9

1 reference

21 May 2018

publication date

1 July 2005

1 reference

21 May 2018

published in

HIV Medicine

1 reference

21 May 2018

volume

6 Suppl 2

1 reference

21 May 2018

page(s)

62-83

1 reference

21 May 2018

The growing burden of tuberculosis: global trends and interactions with the HIV epidemic

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00293.X

Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00293.X

Tuberculosis in patients with the acquired immunodeficiency syndrome. Clinical features, response to therapy, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00293.X

Rapid detection of active and latent tuberculosis infection in HIV-positive individuals by enumeration of Mycobacterium tuberculosis-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00293.X

Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00293.X

Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00293.X

Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00293.X

Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00293.X

Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00293.X

The treatment of tuberculosis in HIV-infected persons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00293.X

P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00293.X

Pharmacokinetic interaction between rifampin and zidovudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00293.X

Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00293.X

Co-administration of rifampin and nevirapine in HIV-infected patients with tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00293.X

Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00293.X

Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00293.X

Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00293.X

Drug malabsorption and resistant tuberculosis in HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00293.X

Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00293.X

Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya. Analysis of early (6-month) mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00293.X

Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00293.X

Directly observed therapy for treatment completion of pulmonary tuberculosis: Consensus Statement of the Public Health Tuberculosis Guidelines Panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00293.X

Randomised controlled trial of self-supervised and directly observed treatment of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00293.X

Effectiveness of the direct observation component of DOTS for tuberculosis: a randomised controlled trial in Pakistan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00293.X

Delayed-type hypersensitivity anergy in human immunodeficiency virus-infected persons screened for infection with Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00293.X

Instability of delayed-type hypersensitivity skin test anergy in human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00293.X

Tuberculin Skin Test Reactivity among Adults Infected with Human Immunodeficiency Virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00293.X

Tuberculin and Anergy Testing in HIV-Seropositive and HIV-Seronegative Persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00293.X

Reliability of anergy skin testing in persons with HIV infection. The pulmonary Complications of HIV Infection Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00293.X

Preventive therapy for tuberculosis in HIV-infected persons: international recommendations, research, and practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00293.X

Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American He

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00293.X

Twice weekly tuberculosis preventive therapy in HIV infection in Zambia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00293.X

Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00293.X

Paradoxical expansion of intracranial tuberculomas during chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00293.X

Paradoxical enlargement or development of intracranial tuberculomas during therapy: case report and review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00293.X

Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00293.X

Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00293.X

Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00293.X

Risk for Developing Tuberculosis among Anergic Patients Infected with HIV

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00293.X

10.1111/J.1468-1293.2005.00293.X

21 January 2018

Identifiers

DOI

1 reference

21 May 2018

PubMed ID

16011537

1 reference

21 May 2018